In the BioHarmony Drug Report Database
Repaglinide
Prandin, NovoNorm (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
Trade Name
|
NovoNorm, Prandin |
|---|---|
Common Name
|
repaglinide |
ChEMBL ID
|
CHEMBL1272 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Antidiabetic, SGLT2 inhibitors, not phlorozin derivatives |
Image (chem structure or protein)